News |

The company announced its previously announced agreement to divest its late-stage ophthalmic assets to Laboratoires Théa S.A.S. has been terminated.

The specialty pharmaceutical research company’s new retinal vascular dysfunction model can have an impact on the research and development of new drugs for retinal vascular diseases.

Kriya is developing a one-time gene therapy designed to block complement C3 and C5, which are clinically validated substrates targeted by FDA approved therapies, to delay the progression of geographic atrophy.

The Lasker-DeBakey Clinical Medical Research Award, dubbed "America’s Nobel," recognizes the wide use of optical coherence tomography to manage eye disease, prevent blindness.

We spoke with researchers and industry professionals at the 2023 ASRS meeting in Seattle, Washington. We asked them, "What do you wish patients knew about eye health?" Here's what Michael Ip, MD, Shawn Kavoussi, MD, and Megan Baldwin, PhD, had to say!

Ocuphire Pharma and Viatris developed the drug together for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents.

We asked, "What do you wish patients knew about eye health?" Here's what Durga Borkar, MD, MMCi, Aaron Lee, MD, and Carl Dazig, MD, had to say!

According to a news release, the J-code for SYFOVRE will become effective on October 1, 2023.

Kiora CEO Brian Strem, PhD, offers an update on the development of KIO-301, a molecule that selectively targets retinal ganglion cells, giving them the ability to sense light.

The research will focus on the compound's impact on biomolecular condensates, which are implicated as a key driver of pathology in neurodegeneration and diseases impacting high metabolic organs. Because the retina is one of the highest energy consuming systems in the human body, deficits in energy supply can be catastrophic.

According to the companies, the partnership will roll out a proprietary system that has earned FDA breakthrough designation, one of the few ophthalmic devices to achieve this status in almost a decade.

To educate patients on the disease, the company has enlisted the help of actor Eric Stonestreet and his mother, Jamey.

Attendees can take advantage of many satellite symposia sponsored by industry. Experts from around the world will present during the symposia.

Researchers from the University of Barcelona are looking to unlock the function of genes in order to design therapies to treat patients diagnosed with retinitis pigmentosa.

Experts in all aspects of retinal care will gather at the RAI Amsterdam Convention Centre, located in the Zuidas business district of the city, which is a short distance from historic Amsterdam with is canals, museums, and shops.

Results from expert surveys provide snapshots of our understanding of DME and shed light on where the 0.19-mg FAc implant stands in the current standard of care.

"Modern Family" actor and his mother, Jamey, are sharing their family’s story of GA and AMD to raise awareness of the disease.

VR will have very useful applications in many fields. One of those fields is ophthalmology.

The theme calls on employers, insurers, and policy makers to consider how they can contribute to improved access to vision and eye health care.

Rather than speculating in a vacuum about the future of remote monitoring in ophthalmology, it is better to explore how other specialties in medicine adopted and integrated remote monitoring into their care plan frameworks.

According to the company, GATHER-2 24-month results met the primary objective of reducing the rate of GA growth in patients treated with IZERVAY compared to sham.

The company has released a video presentation that highlights combining genetic markers with high-resolution retinal imaging to assist in the detection and treatment of blindness and multiple systemic diseases.

Despite its status as an essential postoperative safety eye product and its utilization by every ocular surgeon with every ocular surgery, eye shield innovation has been neglected to date.

Few treatment options available for early stages of disease.

The week of September 18-24 will be dedicated to educating the public on IEDs such as uveitis, keratitis, conjunctivitis and more.

With a robust pipeline, new hope for Stargardt disease and retinitis pigmentosa may be on the horizon.

Garg reported the 30-month data showing that patients receiving pegcetacoplan experienced an increasing treatment effect compared with sham (ie, a decrease in GA lesion area over time).

A panel of retina specialists review new and emerging treatments in neovascular AMD and DME, highlighting high-dose aflibercept and KSI-301. Which emerging treatments are you most interested in?

In recent panel discussions, leaders in the retina space shared their thoughts around AMD and DME. These key quotes showcase the heart of these discussions.

When smokers used both cigarettes and e-cigarettes, studies showed additional detrimental findings, such as lower general health, increased sleep latency, and higher vascular disorder risk.